Articles tagged with Cancer Genetics
Ribosome biogenesis is crucial for liver regeneration, hepatitis C virus infection, nonalcoholic fatty liver disease, liver fibrosis, cirrhosis, and hepatocellular carcinoma. Targeted therapies targeting ribosome biogenesis may offer new treatment options for chronic liver diseases and liver cancer.
Recent findings reveal TET1's dual role in disease progression, inhibiting malignant cell growth in certain cancers while driving oncogenic pathways in others. Abnormal TET1 activity disrupts epigenetic mechanisms, contributing to neurological disorders, metabolic diseases, and autoimmune conditions.
The review highlights the significance of fusion genes across various cancers, including hematological malignancies, lung cancer, thyroid cancer, and prostate cancer. Fusion genes disrupt normal cellular processes, leading to uncontrolled proliferation and metastatic potential.
The review highlights the indispensable value of model organisms in understanding disease pathogenesis, revealing conserved genetic pathways across species. This knowledge accelerates the identification of candidate disease genes and the testing of therapeutic strategies for rare genetic disorders.
PDX models accurately mimic human tumors, offering a powerful preclinical platform for testing novel therapies. These models have demonstrated significant promise in various types of cancer research.
Researchers have discovered a novel cell-clearance pathway linked to diseases such as Chediak-Higashi Syndrome, which affects immune system function. The study used CRISPR/Cas9 gene-editing technology and live imaging to characterize this pathway and identify key genes involved.
A study found significant gaps in testing for genetic cancer risk among patients with womb cancer, with less than half eligible receiving a blood test for Lynch syndrome. This can lead to delayed diagnosis and increased cancer risk, affecting not only the individual but also their family members.
A new study explains how the gene CDK12 drives high-grade serous tubo-ovarian carcinoma, a rare and aggressive form of ovarian cancer. Researchers discovered that inactivating CDK12 triggers an immune cell response and identified a partner gene, CDK13, as a target for a degrader or inhibitor.
The Dresden research team developed an autonomous AI agent for precision medicine that can process multimodal data and have reasoning capabilities. The AI agent reached correct clinical conclusions in 91% of cases and accurately cited relevant oncology guidelines in over 75% of its responses.
The ESMO Gynaecological Cancers Congress 2025 will convene in Vienna, Austria, from June 19-21, featuring novel data on immunotherapy combinations and emerging treatment strategies for rare gynaecological cancers. The congress will also explore innovative approaches using antibody-drug conjugates.
Researchers found that childhood kidney cancers have significantly more genetic changes than previously thought, with some tumors having up to millions of changes. This discovery challenges the existing notion that childhood cancers have few genetic variants and suggests new treatment options such as immunotherapy.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
Researchers examined baseline characteristics of adolescent and young adult (AYA) cancer survivors seen in oncology primary care clinic, finding high rates of comorbidities and cardiovascular disease. They also studied the overexpression of IRAK4 protein in acute myeloid leukemia (AML) cells, with potential implications for treatment.
A survey of stakeholders in Japan found that incorporating patient voices into assessments of genetic conditions can recalibrate people's ideas about seriousness, shifting perceptions from a tool of societal burden reduction to individual reproductive autonomy. The study emphasizes the need for including patient voices in shaping ethic...
A new study published in Blood Cancer Discovery found that certain gene mutations and the maturity of leukemia cells affect how patients respond to venetoclax and hypomethylating agents. Researchers identified a subtype of acute myeloid leukemia with worse outcomes, particularly those without the NPM1 mutation.
A study published in Nature Communications has discovered two genetic variants linked to breast cancer in black South African women, shedding light on the genetic basis of this disease in African populations. The findings have implications for developing targeted treatments and improving cancer risk prediction tools.
DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy, pinpointing mutational escape routes that let cancers resist treatment. The framework reveals which genes may ignite resistance to anticancer drugs, suggesting a core circuitry boosting strategy.
Pennington Biomedical welcomes Dr. Adithya Hari, MD, with expertise in nuclear oncology and translational science, strengthening cancer research and patient-centered innovation in Louisiana. He will establish a research program focused on nuclear medicine and dedicate time to direct patient care through a clinical partnership.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
The treatment demonstrated early signals of efficacy, with 65.7% of patients experiencing lasting stable disease, and was generally well-tolerated, with most adverse events being mild and manageable.
Researchers identified four specific genes linked to lethal stomach cancers, enabling potential targeted treatments and less aggressive procedures for some patients. The study's findings support a more personalized approach to treatment based on each patient's tumor biology.
Researchers developed a saliva test that uses AI to identify genetic mutations in the DPYD gene, which can affect how well cancer patients respond to chemotherapy. The study found several new mutations that could lead to severe side effects from 5-fluorouracil, a widely used chemotherapy drug.
Novel biomarkers like miRNA-34a link anthracyclines to cardiotoxicity, while stem cell therapy and nanotechnology offer potential for prevention and treatment. Traditional strategies have limitations, but new approaches hold hope for improved patient outcomes.
Researchers argue that the current paradigm of cancer as a genetic disease is unproductive due to inconsistencies in sequencing data. Alternative paradigms considering non-genetic processes, such as disruptions in gene regulatory networks and tissue organization, are proposed to guide future experiments.
A new study in the Circulation Journal reveals that babies born with heart defects may be at a higher risk of developing childhood cancer. Mothers of infants with congenital heart defects also show an increased cancer risk. The study highlights the importance of maternal factors and genetic traits in understanding this connection.
Researchers found that pancreatic cancer cells gain a survival edge by carrying copies of critical cancer genes on circular pieces of DNA outside chromosomes. The discovery highlights the importance of targeting extrachromosomal DNA in treating the disease.
Genetic changes triggered by environmental factors like pollution, diet, and stress can increase cancer risk. Nearly everyone is exposed to cancer risk factors daily, highlighting the need for public awareness and policy action to reduce exposure.
Researchers found genetic changes not exclusive to tumours and skin patches, suggesting additional factors are necessary for tumour development. The study identified a pattern of mutations in the NF1 gene that may explain why nervous system tissues are commonly affected.
A recent study reveals genes that may help predict prostate cancer outcomes, including androgen receptor AR-V7 and p160 gene family. The research suggests these genes could serve as potential prognostic biomarkers for prostate cancer, highlighting the importance of androgen signaling in disease progression.
Researchers have developed a new gene therapy that targets aggressive brain cancer, glioblastoma, with a precise delivery system. The treatment uses a novel virus to deliver a targeting drug to cancer cells, achieving cure rates of up to 90% in mouse models.
A multi-institutional study led by Mayo Clinic researchers has improved the accuracy of genetic testing for BRCA2 variants, enabling precise risk assessments and personalized treatment plans. The findings will aid in identifying patients who may benefit from targeted therapies such as PARP inhibitors.
Researchers analyzed individual cells from two craniopharyngioma subtypes to identify specific cell types, their features, and interactions. The study found distinct cell types linked to tumor development and immune response in both adamantinomatous and papillary craniopharyngiomas.
A study by Tulane University researchers found that tumors in female fruit flies grew 2.5 times larger than those in male fruit flies due to sex-based differences in immune response. The stronger innate immune response in females accelerated tumor growth.
The study analyzed DNA from over 100,000 participants and found that nearly 2,000 carried at least one genetic variant linked to these diseases. The findings have led to life-changing discoveries and new insights into personalized medicine.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
A recent study from Uppsala University found that genetic variation in cancer cells can enhance the effects of an already approved cancer drug, talazoparib, against liver cancer cells lacking a functional CYP2D6 enzyme. This suggests a potential for more individually tailored and effective cancer therapies.
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
A new study found significant disparities in at-home test use among older adults, with those having a college degree or higher and higher incomes being more likely to use them. However, Black older adults were less likely to use these tests compared to other racial/ethnic groups.
A new NIH study finds that West African genetic ancestry is linked to increased prostate cancer risk among men living in disadvantaged neighborhoods, possibly due to chronic stress. The study suggests that neighborhood environment may play a role in determining how genetic ancestry influences prostate cancer risk.
A single-center cohort study identified substantial overall survival disparity among racial and ethnic groups, with socioeconomic status contributing less than a third of the disparity. Tumor molecular features also played a significant role in the disparities found in colorectal cancer survival.
Researchers at Huntsman Cancer Institute found that a chatbot can assist patients in deciding whether to pursue genetic testing, offering an alternative to traditional genetic counseling. The study demonstrated equally likely outcomes between the chatbot group and those receiving standard two-appointment model care.
A genetic variant in the Syntaxin 17 gene determines the speed of hair greying and susceptibility to skin melanoma in horses. The study found three gene variants at the Grey locus, with the G3 variant associated with a higher risk of melanoma.
Researchers unveil retrotransposon-derived DNA zip codes that enable myeloma cell internalization, shedding light on cancer evolution and treatment response. The findings highlight the potential of zip-code technology in improving patient outcomes and advancing human health.
The St. Jude gene panel is a cost-effective test that categorizes childhood malignancies and guides patient treatment by sequencing 0.15% of the human genome. The panel outperforms existing cancer gene panels, providing 90% coverage of pediatric cancer driver genes.
Researchers highlight DDX41's distinct contribution to myeloid neoplasms with germline predisposition. The discovery sheds light on unique pathogenesis and disease phenotype associated with DDX41 variants.
A Mayo Clinic study reveals that current genetic screening protocols fail to detect notable numbers of people carrying hereditary breast and ovarian cancer syndrome and Lynch syndrome mutations. The study identified 550 carriers of these mutations, with half being previously unaware of their risk.
Researchers found that bowel cancer cells can regulate their growth using genetic on-off switches, allowing them to maximize survival chances. The study also showed that DNA repair genes can be repeatedly created and repaired, acting as 'genetic switches' to control tumour growth or put the brakes back on.
Researchers at CeMM have identified a synthetic variant inspired by the Withanolides group that acts highly specifically against leukemia cells. The molecule disrupts the cholesterol metabolism of tumor cells.
Researchers have discovered that a rare liver cancer called fibrolamellar carcinoma is not caused by the fusion of two genes, but by the overexpression of a protein called protein kinase A. This finding has potential to reveal pathways for broad range of cancers and offer new treatment possibilities.
Researchers have discovered that a protein called MED12 plays a critical role in pancreatic cancer's development, particularly in basal-like cells. The study builds on decades of research at Cold Spring Harbor Laboratory, which previously identified the importance of p63 for basal cell formation.
A new study by a global consortium provides insight into how tumors evolve, shedding light on the intricate processes underlying cancer evolution. The findings define optimal algorithms to analyze tumor evolution, enhancing diagnostic accuracy and treatment planning.
Researchers discuss Ibrutinib, a BTK inhibitor approved for chronic lymphocytic leukemia treatment, noting 20-25% of patients experience dose-limiting cardiovascular toxicities. A recent study identifies genetic biomarkers, such as KCNQ1 and GATA4, associated with cardiotoxic events, which may improve risk stratification.
Pharmaceutical genomic testing can optimize drug dosages and minimize adverse events in treating metastatic prostate cancer. By understanding an individual's genetic variations, clinicians can tailor treatments more effectively.
The study highlights the importance of protease-activated receptors (PARs) in cancer growth and development, with PH-binding motifs identified as a key platform for drug design. The researchers suggest that targeting PARs could provide an alternative to current oncogenic pathways.
Researchers found a new pathway to cancer cell death led by the Schlafen11 (SLFN11) gene. This discovery could have implications for cancer treatment and patient outcomes.
Researchers found that ARID1A mutation renders tumors sensitive to immunotherapy by triggering an antiviral immune response. This could lead to improved patient outcomes and the development of targeted therapies.
Researchers warn of potential corporate uses of polygenic scores for risk assessment and business profits, highlighting the need for policy safeguards. Current laws and policies are inadequate to address ethical concerns surrounding the use of genetic data.
Breast cancer study reveals seven pivotal genes are upregulated in tumor tissues, indicating critical role in disease progression and poorer patient prognosis. In vitro validation supports overexpression of these genes in breast cancer, emphasizing their importance as potential therapeutic targets.
This study analyzed differentially expressed genes from three datasets to identify hub genes associated with gastric adenocarcinoma. The analysis revealed that genes such as ERBB4 and MAPT were linked to GC progression and had poor overall survival, suggesting potential therapeutic targets.